InvestorsHub Logo
Followers 35
Posts 1771
Boards Moderated 0
Alias Born 09/25/2012

Re: Saltz post# 18285

Wednesday, 11/22/2017 6:03:31 PM

Wednesday, November 22, 2017 6:03:31 PM

Post# of 233291
I agree Saltz. Look in response to Amatuer had Pro-140 had the same side effects at Juluca or other HIV treatments out there then I can see your point on why CYDY shareholders should be worried. That's not the case though. Secondly, if Pro-140 had the same side effects as current treatments then there would be no interest.

What makes Cytodyn unique based on all other HIV medicines currently approved and those approved one day ago is that Pro-140 has no side effects. A second benefit would be that Pro-140 doesn't show to develop drug resistance after a patient has taken it for a long time. These 2 items are key advantages over other competitors. I fail to understand why Amatueur can't see this concept after I have repeatedly explained this to him.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News